Cooper Companies' Sharp Pullback Offers Attractive Entry: Oakmark Global Fund's Strategic Buy

Cooper Companies (NASDAQ: COO) stock price presented a compelling entry point following the sector‑wide pullback in medical technology.

Market Shockwave in the Sector

■Closed at $68.51; one‑month return +7.35%

■‑3.95% decline over the past 52 weeks

■Market capitalization $13.36 billion

Oakmark Global Fund's Fresh Position

In its Q2 2026 investor letter, Oakmark Global Fund added Cooper Companies to its portfolio, targeting a 7.89% return that lagged the MSCI World Index's 13.76% performance.

■Energy and industrials drove top‑line gains

■Healthcare and consumer discretionary detracted

■AI remained a core market theme

Valuation and Entry‑Point Assessment

■Contact‑lens market is oligopolistic, with high entry barriers and recurring revenue streams

■Cooper's specialty‑lens market‑share gains and private‑label strategy provide a competitive moat

■Recent steps to improve free‑cash‑flow conversion and optimize the product portfolio signal upside

■Stock trades at a meaningful discount to public peers, private transactions, and its own historical levels

Takeaway and Investment Verdict

■Intrinsic value estimate 5‑7% above current price

■Short‑term medical‑tech sector pressure balanced by long‑term dividend and growth potential

■Cooper's market‑share expansion and cash‑flow improvements make the stock an attractive entry point

Markets view Cooper Companies' modest pullback as an opportunity. The oligopolistic nature of the medical‑device segment, sustainable cash flow, and strategic pricing align with Oakmark Global Fund's long‑term value‑creation objectives. Amid persistently high Asia‑Pacific risks, focusing on a U.S.‑based health‑care player offers sensible diversification and risk‑management benefits.